Joanne Schindler
Chief Tech/Sci/R&D Officer bij FUSN PHAR
Profiel
Joanne Schindler is currently the Executive VP, Head-Medical & Clinical Development at Fusion Pharmaceuticals, Inc. Prior to her current position, she served as the Vice President-Clinical Development at Constellation Pharmaceuticals, Inc. and H3 Biomedicine, Inc. She also held the role of Chief Medical Officer at IMV, Inc. from 2019 to 2021.
Dr. Schindler completed her undergraduate degree at Brandeis University and obtained a doctorate from The University of Connecticut School of Medicine.
Actieve functies van Joanne Schindler
| Bedrijven | Functie | Begin |
|---|---|---|
| FUSN PHAR | Chief Tech/Sci/R&D Officer | 30-06-2022 |
Eerdere bekende functies van Joanne Schindler
| Bedrijven | Functie | Einde |
|---|---|---|
| IMV INC. | Chief Tech/Sci/R&D Officer | 11-06-2021 |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Joanne Schindler
| Brandeis University | Undergraduate Degree |
| The University of Connecticut School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| IMV INC. | Health Technology |
| FUSN PHAR | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The private company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
